We are raising funds to develop a dedicated therapy suite for patients who require new targeted therapies for prostate cancer.

Background

About 1 in 7 men will be diagnosed with prostate cancer at some time during their life. In the UK prostate cancer is the most common cancer in men, with around 52,000 men diagnosed every year (2016-2018 data). The incidence rate of prostate cancer is expected to increase by 15% between 2023-2025.

Mount Vernon Cancer Centre sees a large volume of prostate cancer patients. Whilst the radical treatment approach can vary, longer-term management of palliative patients has increased. As more patients are living with cancer, ongoing symptomatic management and symptom-free survival is increasing.

Lutetium-177 (177Lu)-PSMA is a new innovative therapy, where a radioactive dose is injected into the patient, targeting the disease and treating it directly, unlike chemotherapy, which treats the body as a whole.

The Nuclear Medicine Department would like to offer this new therapy to their prostate cancer patients. However, to offer this treatment, refurbishment of the existing patient waiting area and therapy rooms is needed.

“At Mount Vernon Cancer Centre we pride ourselves in offering a wide range of advanced and innovative treatments for cancer. By offering Lutetium we are expanding the range of treatment options available to prostate cancer patients requiring longer term supportive care.

A new nuclear medicine therapy suite will mean we can offer patients more targeted molecular therapies in a calm, friendly and comfortable environment without the need to have an overnight stay on our wards.” –

Jagdeep Kudhail, Head of Radiation Services

We would really appreciate any donations to our page for this amazing cause.